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Abstract. The therapeutic potential of targeting tumor endo-
thelium and vascular supply is now widely recognized to
treat different diseases. One such disease is cancer; where
endothelial cells are actively proliferating to support the tumor
growth. Solid tumors cannot grow beyond the size of a few
millimeters without inducing the proliferation of endothelium
and formation of new blood vessels. Hence it is crucial to
search for new agents that selectively block tumor blood
supply. These include anti-angiogenic molecules, vascular
disrupting agents or endothelial disrupting agents. The anti-
angiogenic molecules such as monoclonal antibodies and
tyrosine kinase inhibitors disrupt endothelial cell survival
mechanisms and new blood vessel formation, and vascular
disrupting agents for instance ligand-directed and small
molecules can be used to disrupt the already existing abnormal
vasculature that support tumors by targeting their dysmorphic
endothelial cells. The recent advances in this area of research
have identified a variety of investigational agents which are
currently in clinical development at various stages and some
of these candidates are already approved in cancer treatment.
This report will review some of the recent developments and
most significant advances in this field and outline future
challenges and directions. 
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1. Introduction
Angiogenesis is essential to maintain closed circulatory
system and also for supplying oxygen and nutrients to various
tissues in the body (1,2). It is well known that tumors need
an ongoing blood supply to grow beyond a minimum size
of 2-3 mm3 (3). Tumors start as avascular masses which
initially depend on pre-existent vasculature in their micro-
environment (4). However, when tumor tissues grow beyond
the limit of oxygen diffusion, hypoxia induces vessel growth
by signaling through hypoxia inducible transcription factors
(HIFs) (5). These factors induce the production of pro-
angiogenic compounds such as vascular endothelial growth
factor (VEGF), angiopoietin (Ang)-1, placental growth factor
(PlGF), and various cytokines (6).
Targeting tumor vascular supply is widely recognized for
its therapeutic potential. A variety of investigational agents
have been developed as a result of intense research and
development leading to currently available drugs/agents for
clinical trials. These novel agents target the endothelium or
vasculature of the tumors which make these agents quite
distinct from the cytotoxic drugs conventionally used in the
treatment of solid tumors. Recently, Chang et al showed that
anti-angiogenic targeting liposomes increase therapeutic
efficacy of solid tumors and anti-angiogenic ligand-targeted
therapy is highly beneficial over conventional anticancer
drug therapy (7). 
More than 90% of all cancers present as solid tumors
which depend on a functioning vascular network to supply
oxygen and nutrients and interfering with this network holds
a great promise for cancer therapy. Conventional anticancer
treatments exert their effect by targeting the rapidly growing
neoplastic cell population; however vascular-targeted therapies
elicit an indirect effect on the tumor cells. Targeting a com-
ponent distinct from the one targeted by cytotoxic agents will
provide a great potential for complementary and/or synergistic
activity. A significant effect may take place because blockage
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or destruction of a single blood vessel may result in tumor
cell starvation and death. In some tumors, the endothelial cell
does not need to be directly killed by the drugs; a change of
structure or local initiation of the coagulation cascade may be
all that is needed. In addition, endothelial cells are normal,
untransformed cells and therefore have greater genetic stability
than the neoplastic cells and are less likely to acquire drug
resistance (8). 
Vessel ligation and transcatheter arterial embolization
are examples of early attempts to interfere with tumor blood
supply (9). Even though these approaches were invasive and
are associated with a number of non-selective effects resulting
in normal tissue damage, they provide clear evidence that the
vasculature is a possible target to inhibit solid tumor growth.
Recent developments in this therapeutic area have now
resulted in a wide variety of selective agents with known
targets. 
Generally, there are two approaches to target the vascu-
lature of a tumor. The first approach is to target and inhibit
new blood vessel formation in tumors by anti-angiogenic
agents (8,10-14). The second approach is to target and destroy
existing tumor blood vessels by vascular disrupting agents
(VDA) (15-20). These agents differ from each other in three
major aspects: physiological target, the stage of disease, and
the treatment scheduling (Table I).
2. Anti-angiogenesis strategies
Angiogenesis is the formation of new blood vessels from the
pre-existing ones and it is a physiological process in embryo-
genesis and development. During adulthood the proliferation
rate of endothelial cells is usually very low compared to other
cell types (21) except in wound healing and in the endometrium
and ovaries where physiological angiogenesis takes place.
However, pathological angiogenesis is observed in a variety
of disorders such as diabetic retinopathy, rheumatoid arthritis,
atherosclerosis, psoriasis, as well as in solid tumors and
metastasis. Tumor angiogenesis is an extremely complex
process. It is under dynamic regulation by stimulatory [e.g.,
VEGF, platelet-derived growth factor (PDGF), basic fibroblast
growth factor (bFGF), interleukin-8 (IL-8), matrix metallo-
proteinases (MMPs)] and inhibitory [e.g., tumor necrosis
factor (TNF), serotonin (5HT), nitric oxide, angiostatin or
endostatin] factors released by tumor and host cells.
In tumors, cells are initially oxygenated and nourished
by simple diffusion, but when tissues grow beyond the limit
of oxygen/nutrient diffusion, the tumor microenvironment
changes and the tumor cells become dominant with hypoxia,
hypoglycaemia, bicarbonate depletion, hypercapnia, high
lactate levels and acidosis (22). For further growth, tumors
must develop an angiogenic phenotype. Tumor angiogenesis
involves several processes, including proliferation of endo-
thelial cells, proteolytic degradation of the extracellular matrix
and migration of endothelial cells, leading to the formation of
a functioning vessel with a lumen (23).
In the last few years, different strategies have been used
to inhibit angiogenesis which resulted in new candidate
molecules that have been tested in preclinical and clinical
trials. The use of antibodies showed that antibody therapy
was effective and promising. In addition, small molecules,
mainly inhibitors of receptor tyrosine kinases, have been
designed and their potential effect for tumor therapy is
currently under investigation. In principle, both approaches
can inhibit angiogenic processes. While monoclonal antibodies
can sequester molecular mediators such as VEGF-A, small
organic molecules can interfere with intracellular signaling
and protein expression. The two molecular approaches are
likely to be complementary, as they act at the level of different
molecular targets.
a) Monoclonal antibodies. Because monoclonal antibodies
have high affinity and specificity, some may be given in high
doses; higher than expected and therefore, represent a class
of safe therapeutic agents that can easily be combined with
standard chemotherapeutic regimens. Monoclonal antibody
derivatives have shown an impressive selectivity by localizing
around tumor blood vessels and mediating tumor therapy in
animal models of cancer. Recent advances in proteomic
research have made it possible to screen for selective molecular
targets on the endothelium and vasculature of tumors. In this
section we will discuss some of these important targets. 
i) VEGF/VEGF-receptors. VEGF (particularly VEGF-A) is
considered as the most important and potent pro-angiogenic
(survival) factor involved in tumor growth and metastasis
(24). Expression of VEGF mRNA is induced by different
growth factors and cytokines, including platelet derived
growth factor PDGF, epidermal growth factor EGF, TNF-·,
transforming growth factor TGF-ß and IL-1ß (21). VEGF-A
promotes blood vessel formation by binding and activating
VEGF receptor 2 (VEGFR2/KDR) and at the same time
increases vascular permeability and contributes to endothelial-
cell survival and proliferation in blood and lymphatic vessels.
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Table I. Differences between anti-angiogenic and vascular disrupting agents.a
––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––– 
Agents Physiological target Stage of disease Treatment schedule
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Anti-angiogenic agents New blood vessel formation Early stage (preventive action) Chronic administration
Vascular disrupting agents Established blood vessels Advanced stage (immediate effect) Acute administration
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
aChronic administration of anti-angiogenetic agents target the formation of new blood vessels and which are used in the early stages of
disease which could impacts in the prevention or spreading of the disease, while vascular disrupting agents target established blood vessels
and their acute administration is beneficial in advanced stage of the disease.
––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––– 
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Application of antibodies targeting either VEGF-A or
VEGFR-2 is a promising strategy to block VEGF-A function.
In 2004, the Food and Drug Administration (FDA) approved
a recombinant humanized antibody bevacizumab (Avastin,
Genentech/Roche) which targets all isoforms of human
VEGF-A. Phase II clinical trials have been conducted in a
wide range of malignant diseases focusing mainly on
colorectal cancer (CRC), which shows high expression of
VEGF and its receptors (25). 
Phase III clinical trials were conducted in untreated,
metastatic CRC and bevacizumab in combination with
irinotecan/5-fluorouracil chemotherapy was compared to
chemotherapy alone. The duration rate of therapeutic
response, progression-free survival and overall survival
was significantly improved by bevacizumab compared
with placebo (26). A phase III study in breast cancer patients
showed that bevacizumab combined with capecitabine has
a highly significant increase of overall-response-rate but
no effect on progression-free survival when compared with
capecitabine alone (27). Bevacizumab was also investigated
for its efficacy in the treatment of other cancers including
breast cancer, lung cancer and hematological cancers (28,29). 
In October 2006, FDA granted a labeling extension to
bevacizumab for the treatment of advanced stage non-small
cell lung cancer (NSCLC) along with carboplatin and
paclitaxel (30). The addition of bevacizumab to first-line
chemotherapy improved response rate and progression-free
survival among the patients with advanced stage NSCLC. A
randomized phase II trial of patients with newly diagnosed
advanced NSCLC treated with standard platinum based
chemotherapy with placebo or bevacizumab (at either 7.5 vs.
15 mg/kg) demonstrated a higher response rate and increase
in overall survival with the higher dose of bevacizumab
compared to placebo (30,31).
Another humanized monoclonal antibody that targets
isoforms 121 and 165 of VEGF-A has been developed and
investigated. This antibody is called HuMV833 and has shown
to localize to tumor metastases in patients in a PET experiment
(32). Recently, a phase I dose escalation study was performed
on patients with advanced cancer and has demonstrated good
tolerability and even some clinical activity (33). In addition
to the previous antibodies, a murine VEGF antibody has
been designed (2C3). It is an IgG2a that inhibits the binding
of VEGF to VEGFR2 but not to VEGFR1 (34). However,
comparison efficacy and toxicity studies of the humanized
version of 2C3 with less specific antibodies have not been
investigated yet.
The VEGF-trap is a different antibody approach that has
been used to inhibit VEGF activity. It is a fully humanized
soluble composite decoy receptor generated by fusing the
extra-cellular domains of VEGFR-1 and VEGFR-2 to the Fc
portion of human IgG1 (35). This decoy not only binds to
VEGF-A but also to PlGF and VEGF-B. In vivo studies using
mice xenograft models treated with VEGF-trap have shown
promising results (36). In addition, a phase I clinical dose
escalation study showed acceptable tolerability (37); however,
the efficacy of VEGF-trap in cancer treatment needs to be
proven (38). Another important target in the VEGF pathway
is VEGFR-2. In the last few years, a new human antibody
(IMC-1121) has been designed to target VEGFR-2. This
antibody prevents VEGF binding and therefore the receptor
downstream signaling (39). The IMC-1121 antibody has
been shown to significantly prolong survival of animals grafted
with human leukemia cells (40).
ii) EGFR2 (HER2-receptor). It has been shown that the
EGF receptor 2 protein (HER2; ErbB2) is overexpressed in
30% of breast cancer patients and this amplification correlates
with poor clinical prognosis (41,42). HER2 is implicated in
the over-expression of VEGF through hypoxia-inducible
factor 1 alpha (HIF1·) under hypoxic conditions and even
through hypoxic-independent mechanisms (43). A humanized
monoclonal antibody to the extracellular domain of the HER2
receptor (Trastuzumab, Herceptin) is currently being used
to treat breast cancer patients (44,45). The antibody binds to
HER2 which then lead to internalization and thereby down-
regulation of the receptor, inhibition of cell cycle progression,
and antibody-dependent cellular cytotoxicity by inducing
an immune response (46). Trastuzumab has been shown to
inhibit angiogenesis in both the in vitro (47) and in vivo models
(48,49). 
Pertuzumab (Omnitarg, 2C4) is another antibody to the
HER2 tyrosine kinase receptor that has entered clinical trials
(42,50-53). A phase I study showed that pertuzumab is
clinically active and well tolerated (51) and was then further
investigated in phase II trials for ovarian, lung and prostate
cancers (42). A synergistic effect of trastuzumab and per-
tuzumab has been shown in in vitro studies in breast cancer
cells (51).
iii) Integrins. Inhibition of the adhesive interaction of
vascular endothelial cells during angiogenesis represents
another target for the endothelial cells and anti-angiogenesis
therapy. Integrin ·vß3 is a member of a large family of cell
surface proteins that mediate cell-matrix and cell-cell inter-
actions. Studies have shown that this protein plays an important
role and is upregulated during angiogenesis (54). A murine
antibody, LM609, to the vitronectin receptor integrin ·vß3
selectively localized to blood vessels in a breast cancer model
and was able to localize at the tumor site in a magnetic
resonance imaging setup in rabbits (55). In addition, LM609
significantly inhibited tumor growth when administered
intravenously to tumor-bearing mice. Analysis of treated
tumors showed significantly fewer blood vessels, suggesting
an anti-angiogenic effect of the tested compound (56). Another
approach has been used to target integrin ·vß3 using tripeptide
RGD which selectively recognizes the vitronectin receptor
and localizes to tumor blood vessels in vivo (57,58). 
These findings have been used to design a fusion protein
containing the RGD sequence and the Fc-fragment of a mouse
IgG in order to target the tumor endothelium thereby eliciting
an anti-angiogenic immune response. It has been demonstrated
that the fusion protein inhibited tumor angiogenesis and tumor
growth in vivo and improved overall survival in animals (50).
b) Small molecules (inhibitors of receptor tyrosine kinases and
others). Receptors for VEGF are members of the tyrosine
kinase family and were initially identified on endothelial
cells (59). There are three members of the VEGF receptor
family: VEGFR-1(Flt), VEGFR-2 (Flk/KDR) and VEGFR-3
(Flt4). All three are receptor-type tyrosine kinases, which are
expressed primarily, though not exclusively, by endothelial
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cells. The first two bind the classical VEGF (VEGF A) and the
latter interacts with VEGF C and D. At present, the mitogenic
actions of VEGF are thought to be mediated primarily by
VEGFR-2. VEGFR-1 binds the ligand with a greater affinity
than VEGFR-2. An alternatively spliced form of VEGFR-1,
lacking the seventh immunoglobin-like structure and both the
transmembrane and cytoplasmic domains, has been identified
in human umbilical vein endothelial cells (HUVEC) cells.
Since this receptor binds VEGF with high affinity and prevents
VEGF-induced mitogenesis, it may represent a negative
regulator of angiogenesis. Following receptor activation in
endothelial cells, a number of cellular responses occur that
are likely to play a role in angiogenesis and tissue remodeling.
For example, induction of urokinase and urokinase receptors,
tissue plasminogen activators (PA), PA inhibitors, metallo-
proteinase activity, vascular cell adhesion molecule-1 and
intercellular adhesion molecule-1 expression and hexose
transport (60,61). One of the strategies for antagonizing
VEGF-induced angiogenesis is to inhibit the kinase activity of
its receptor. This has been shown to be a promising therapeutic
approach to stabilize the progression of solid malignancies by
abrogating tumor-induced angiogenesis. In the last few years
several kinase inhibitors have been investigated in preclinical
and clinical aspects.
i) AZD2171 is an indole-ether quinazoline receptor kinase
inhibitor. Wedge and co-workers have shown that AZD2171
is a potent ATP competitive inhibitor of recombinant KDR
tyrosine kinase in vitro (62). Concordant with this, in HUVEC,
AZD2171 inhibited VEGF-stimulated proliferation and KDR
phosphorylation. In a fibroblast/endothelial cell co-culture
model of vessel sprouting, AZD2171 also reduced vessel area,
length and branching. Similarly, the growth of established
human tumor xenografts (colon, lung, prostate, breast and
ovary) in athymic nude mice was inhibited in a dose-dependent
manner by AZD2171 with chronic administration (62). 
ii) BAY 43-9006 is a bi-aryl urea that can significantly
inhibit Raf-1, a member of the RAF/MEK/ERK signaling path-
way. The RAS/RAF signaling pathway is one of the important
mediators of tumor cell proliferation and angiogenesis.
BAY 43-9600 has been shown to be a novel dual inhibitor of
RAF and VEGFR-2 that targets tumor cell proliferation and
angiogenesis (63).
It has been demonstrated that BAY 43-9006 has significant
activity against several receptor tyrosine kinases involved in
neo-vascularization and tumor progression, including
VEGFR-2, VEGFR-3, PDGFR-ß, Flt-3 and c-Kit. After potent
inhibition of VEGFR-2, PDGFR-ß, and VEGFR-3 cellular
receptors auto-phosphorylation was also observed for BAY
43-9600. In xenograft models, it has been shown that daily
administration of BAY 43-9600 demonstrated broad spectrum
anti-tumor activity in colon, pancreatic and breast tumor cell
lines expressing mutant KRAS, wild-type or mutant BRAF. In
sharp contrast, non-small cell lung cancer cell lines expressing
mutant KRAS were insensitive to inhibition of the mitogen
activated protein kinase pathway by BAY 43-9600. 
iii) CP-547,632 is an isothiazole tyrosine kinase inhibitor
of VEGFR-2 and FGF kinases. One study has shown that
CP-547,632 can inhibit VEGF stimulated auto-phosphorylation
of VEGFR-2. The same study also reported that after oral
administration of CP-547,632 to mice bearing NIH3T3/H-ras
tumors, VEGFR-2 phosphorylation was inhibited in a dose-
dependent fashion (64).
iv) CEP-7055 is the fully synthetic orally active N,N-
dimethyl glycine ester of CEP-5214, a C3-(isopropylmethoxy)
fused pyrrolocarbazole with potent pan-VEGFR kinase
inhibitory activity. CEP-5214 has been shown to inhibit
VEGFR2/KDR kinase, VEGFR1/FLT-1 kinase and VEGFR3/
FLT-4. In HUVEC, VEGF-stimulated VEGFR2/KDR auto-
phosphorylation was inhibited by CEP-5214. In addition,
CEP-5214 revealed a dose-related inhibition of microvessel
growth ex vivo in rat aortic ring explant cultures (65).
v) PTK787/ZK 222584 [1-(4-chloroanilino)-4(4-pyridyl-
methyl) phthalazine succinate] is another potent inhibitor of
VEGFR tyrosine kinases. It inhibits other class III kinases,
such as the PDGFR-ß tyrosine kinase, c-Kit and c-Fms.
However, PTK787/ZK 222584 shows no inhibitory activity
against EGFR, FGFR-1, c-Met, Tie-2 or intracellular kinases
such as c-Src, c-Abl and protein kinase C-·. PTK787/ZK
222584 inhibits VEGF-induced autophosphorylation of the
kinase insert domain containing receptor (KDR) endothelial
cell proliferation, migration and survival in nanomolar range
in cell based assays. PTK787/ZK222584 does not have any
cytotoxic or anti-proliferative effects on cells that do not
express VEGF receptors. In animal models, it has been
shown that oral administration of PTK787/ZK 222584 can
inhibit VEGF and PDGF-induced angiogenesis (66).
vi) KRN633 is a selective tyrosine kinase inhibitor for
VEGFR-1, -2 and -3. It has been shown that KRN633 also
inhibits the activation of mitogen-activated protein kinases by
VEGF, along with HUVEC proliferation and tube formation.
In the in vivo tumor xenograft model in mice and rats, KRN633
was able to inhibit the growth of lung, colon and prostate
tumors (67).
vii) SU11248 is a novel small molecule receptor tyrosine
kinase inhibitor with direct anti-tumor as well as anti-
angiogenic activity via targeting VEGF, PDGF, KIT and
FLT3 receptor tyrosine kinases. SU11248 is able to exert
direct anti-tumor activity against tumor cells that rely on
RTKs for proliferation and/or survival, but is also able to
indirectly inhibit tumor growth by inhibiting angiogenesis.
Anti-tumor activity of SU11248 in mouse xenograft models
was investigated and target phosphorylation was measured
and correlated with plasma inhibitor levels. It has been
shown that SU11248 selectively inhibited Flk-1/KDR (VEGF
receptor-2) and PDGFR-ß phosphorylation (in a time- and -
dose-dependent manner) when plasma concentrations of
inhibitor reached or exceeded 50-100 ng/ml. In mouse xeno-
graft models, SU11248 exhibited broad and potent anti-tumor
activity causing regression, growth arrest, or substantially
reduced growth of various established xenografts derived
from human or rat tumor cell lines. The pharmacokinetic/
pharmacodynamic relationship established for SU11248 in
the preclinical studies has aided in the design, selection and
evaluation of dosing regimens in human trails (68).
viii) ZD6474 (Zactima) is a heteroaromatic substituted
anilinoquinazoline that acts as a potent inhibitor of the
VEGFR2 tyrosine kinase activity (69-71). This agent also has
activity against the EGFR tyrosine kinase (70) but to a far
lesser extent. The efficacy of combining ZD6474 (Zactima)
with single and fractionated dose radiation exposures was
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examined in a human colorectal carcinoma model using
HT29 cells. ZD6474 increased the response of HT29 xeno-
grafts to both single and fractionated dose radiotherapy. This
study indicates that ZD6474, when used in conjunction with
radiation therapy, has a clear therapeutic advantage providing
a rationale for considering the combination of this agent with
radiotherapy in the clinic. In one in vivo study, ZD6474
has been shown to significantly reduce the vessel density in
treated tumors. It has a bioavailability profile consistent
with chronic, oral administration and is currently undergoing
clinical trials (72,73). In human tumor xenograft models of
diverse tissue (lung, breast, prostate, colorectal, vulval)
origin, chronic (once daily) administration of ZD6474 led
to dose-dependent inhibition of tumor growth (71,74). It
was also reported in the xenograft model that ZD6474 has
high activity against several central nervous system tumors
including gliomas (75). While there have been some recent
drawbacks in the development of tyrosine kinase inhibitors
(e.g., PTK/ZK; Schering/Novartis), a number of novel
members of the same class have shown promising effects
in clinical trials and some have been approved for clinical
use. SU11248/sunitinib (Sutent) and BAY-43-9006/sorafenib
(Nexavar) are example of tyrosine kinase inhibitors that have
been approved recently as monotherapies for kidney cancer
(76,77).
Small molecules, other than tyrosine kinase inhibitors, can
also target angiogenesis pathways and have been investigated.
These molecules can target the VEGF pathway indirectly by
inhibiting VEGF and/or VEGFR protein expression. Hypoxia
is a major pathway for regulation of VEGF expression in
tumor and non-tumor tissue (78-80) in part because of up-
regulation of hypoxia-inducible factor-1· (HIF-1·). HIF-1·
forms a transcriptionally active HIF-1·-HIF-1ß complex that
interacts with a distal hypoxia-responsive element in the VEGF
gene promoter. Enhanced VEGF expression in cells/tissues
has also been linked to other factors, including cytokines,
mitogens, activation of kinase signaling pathways, oxidative
stress, and hormone stimulation (81-85). It has been shown that
enhanced VEGF stimulation by some of these factors involves
direct or indirect activation of members of the specificity
protein (Sp) family bound to one or more GC-rich motifs
located in the proximal region of the VEGF promoter
(81,82,84,85). For example, PDGF-enhanced expression of
VEGF in NIH3T3 cells involves Sp1 and Sp3 bound to the
-85 to -50 region of the VEGF promoter (81). Oxidative
stress-induced activation of kinases enhances VEGF expression
in gastric cancer cells through increased Sp1-dependent
activation of the same proximal GC-rich sites (84). Stoner
and co-workers have shown that hormone-induced VEGF
expression in ZR-75 breast cancer cells required ER·/Sp1
and ER·/Sp3 interactions with the proximal GC-rich
VEGF promoter elements (85). A recent study (86) further
investigated the role of Sp1 and other Sp proteins in regulation
of VEGF and proliferation of human pancreatic cancer cells.
The results of the VEGF studies confirm that the proximal
GC-rich sites are required for expression of VEGF; however,
the results of RNA interference studies showed that multiple
Sp proteins are involved in VEGF regulation. Sequential
knockdown of Sp1, Sp3 and Sp4 showed that all three proteins
regulated transactivation of VEGF promoter. Sp4 expression
has not been extensively investigated in cancer cells, and
these results suggest that the angiogenesis and metastatic
potential of pancreatic tumors may also be dependent on
levels of Sp4. These and other studies have shown a direct
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Figure 1. Effect of NSAIDs and COX-2 inhibitors on VEGF expression in cancer cells. (A) SW480 colon cancer cells were transfected with VEGF promoter
constructs, treated with the COX-2 inhibitors celecoxib (Cel), nimesulfide (NM), or NS-398 (NS), and luciferase activity was determined (91). (B) Panc-1
pancreatic cancer cells were transfected with the same construct and treated with tolfenamic acid and a structurally related compound (Diclofenac sodium) (92).
Decreased activity was observed in all treatment groups compared to the vehicle treated groups (DMSO control).
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linkage between expression of Sp proteins in various tumors,
VEGF overexpression and have suggested that Sp proteins
can be important targets for new anti-angiogenic agents.
In the last few years several strategies have been used to
target Sp in several tumors. For example, Ishibashi and
coworkers transfected Sp1 decoys(GC-rich oligodeoxy-
nucleotide) into human lung A549 adenocarcinoma and
human glioblastoma multiform U251 cancer cell lines and
inhibited TNF·-induced VEGF gene/protein expression (87).
In addition, cyclooxygenase 2 (COX-2) inhibitors such as
celecoxib are being developed as anticancer drugs, and there
is considerable evidence showing that these compounds
exhibit anti-angiogenic activity (88,89). A recent study has
linked the anti-angiogenic effects of celecoxib in pancreatic
cancer cells to modulation of Sp1 transcription factor activity
(90). This study showed that celecoxib inhibited pancreatic
tumor growth and decreased liver metasasis in an athymic nude
mouse model, and this was paralleled by growth inhibition
and decreased VEGF protein expression in pancreatic cancer
cells.
These observations suggest that the anti-angiogenic activity
of celecoxib in pancreatic cancer cells is linked to targeted
dephosphorylation of Sp1. Ongoing research (91) has also
investigated the mechanisms of action of COX-2 inhibitors
and non-steroidal anti-inflammatory drugs (NSAIDs) and
their effects on cancer cell proliferation and VEGF expression
in colon, pancreatic and other cancer cell lines. The growth
inhibitory effects of these compounds are accompanied by
downregulation of activity in colon cancer cells transfected
with various pVEGF constructs (Fig. 1A), and this was
accompanied by decreased expression of Sp1 and Sp4 but
not Sp3 proteins. Since regulation of VEGF is dependent on
Sp1, Sp3 and Sp4, results show that decreased expression of
VEGF in SW-480 and other colon cancer cells treated with
celecoxib, nimesulfide or NS-398 is due to downregulation
of Sp1 and Sp4. It was also shown that decreased Sp1/Sp4 by
COX-2 inhibitors/NSAIDs in colon cancer cells was COX-2-
independent and due to activation of proteasomes which
specifically target degradation of Sp1 and Sp4 (91). These
results suggest that further development of this degradation
pathway and its specificity may be an important new approach
for drug-induced inhibition of angiogenesis.
Recent studies from our group showed that Tolfenamic acid
and structurally related biaryl derivatives induced degradation
of specific Specificity protein (Sp) transcription factors,
Sp1, Sp3, and Sp4 in pancreatic cancer cells and inhibited
VEGF mRNA and protein expression; this inhibition was
associated with the decreased Sp-dependent activation of the
VEGF promoter (Fig. 1) (92). In orthotopic mouse model for
pancreatic cancer, treatment with tolfenamic acid (50 mg/kg
of body weight) significantly decreased the tumor size; tumor
weight (Fig. 2); VEGF expression; blood vessels density
(Fig. 3) and liver metastasis (92,93). Currently tolfenamic
acid is in phase I clinical trials at M.D. Anderson Cancer Center
Orlando to test on patients with upper gastrointestinal cancers.
3. Vascular disrupting strategies
Tumor endothelial cells proliferate more rapidly than their
counterparts in normal tissues and it has been proposed that
the properties of tumor endothelium may be different from
normal tissue. These differences could be exploited by selective
drugs or agents, now called vascular disrupting agent (VDAs)
or vascular targeting agents (VTA) (94). Several reports have
shown that biological differences between normal and tumor
vascular endothelium (Table II) can provide a scientific
rationale for vascular targeting and therapeutic benefits
(37,94-101). Multiple tumor endothelial markers that are not
expressed on normal vascular endothelium are now being
characterized and used for specific targeted purposes (97).
The target of VDAs is either the endothelial cells lining tumor
vessels or a protein produced by the tumor endothelium
(58,102). Anti-tumor effects in this situation are mediated
by either induction of the endothelial and subsequent tumor
cell apoptosis or by hemorrhagic necrosis as a result of vascular
shutdown (95,103).
Two classes of VDAs are being developed. The first class
is ligand-based, which utilize antibodies and peptides to
deliver toxins, pro-coagulant or pro-apoptotic effectors to
tumor-associated vessels. In the second class, small molecules
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Figure 2. Tolfenamic acid decreased the tumor formation in orthotopic
pancreatic mice. Athymic nude mice were injected with L3.6 pl cells ortho-
topically and treated with tolfenamic acid (25 mg/kg) or vehicle (control
group) for 4 weeks. Tumor volume and weights were analyzed and it was
found that tolfanamic acid treatment resulted a significant decrease in both
the tumor size and weight (93). 
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do not specifically localize to such vessels, but exploit the
differences between normal and tumor endothelium to induce
selective vascular dysfunction and shutdown of tumor blood
vessels. Both types of VDA produce a characteristic pattern
of central necrosis, leaving a peripheral rim of viable tumor
cells (104-108). 
a) Biological vascular-disruptive agents (ligand-directed). In
this approach, a targeting molecule, such as an antibody or
growth factor, is coupled with a toxin or pro-coagulant (e.g.,
ricin or gelonin) and is used to selectively track these agents
to tumor endothelium. Different and unique surface markers
are expressed on vascular endothelial cells of different tissues,
therefore the development of drugs to selectively target tumor
endothelium is quite possible and promising (15). Several
possible target molecules (6) are overexpressed on the tumor
endothelium and these include targets involved in angiogenesis
and remodeling (e.g., VEGF receptors, fibronectin ED-B
domain, ·vß3 integrin) (10);  cell-adhesion molecules, which
are induced by inflammatory mediators secreted by tumors
and normal cells (e.g., vascular cell adhesion molecules
(VCAM-1), E-selectin, N-cadherin) and targets (5) associated
with pro-thrombotic changes that occur on tumor endothelium
(e.g., phosphatidylserine, a tumor endothelium surface
phospholipid). The possible outcome of such treatment
includes thrombosis within tumor vasculature caused by direct
injury or apoptosis, initiation of an immune attack on the
tumor vasculature or a change of conformation of the tumor
endothelium, which leads to occlusion of the tumor vessels. 
Many different approaches to target endothelial cells,
including the use of endothelial cell-specific promoter
elements and vectors with restricted cellular tropisms, have
been explored and show promising results (109,110). In one
study, IL-12 was coupled to humanized IgG antibody to
the fibronectin ED-B domain and this showed anti-vascular
activity in pre-clinical models (111). Another study showed
that monoclonal antibody 3G4, to phosphatidylserine, localizes
to the tumor endothelium in pre-clinical models, and enhances
the efficacy of docetaxel against human breast carcinoma
cell lines with 50% regression (112). In addition, integrins
and aminopeptidase N are thought to be critical for malignant
vasculature and angiogenesis, since inhibitors of these proteins
possess anti-tumor activity. In one study, it has been suggested
that phage libraries can be used to determine specific peptide
sequences of integrins, which allow phages to localize to
specific organs (113). These peptide sequences are known
as ‘vascular addresses’ and expected future research in this
area may lead to the development of ‘organ-specific’ VDAs.
Several other approaches are in pre-clinical development and
these includes VEGF121-gelonin conjugate, a tumor vessel-
targeted liposome to CD31 and duramycin-IgG conjugate
targeted to phosphatidylethanolamine on tumor blood vessels
(56). 
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Figure 3. Reduction of blood vessel density in a pancreatic tumor by tolfenamic acid. In an orthotropic model of human pancreatic cancer (athymic nude mice
injected with L3.6 pl cells), mice were treated with vehicle (corn oil) or with tolfenamic acid by oral gavage for 4 weeks. Staining with antibodies to
determine microvessel density showed decreased CD31 staining in tumors from mice treated with tolfenamic acid when compared to tumors from vehicle
treated (control) animals. These results demonstrate that tolfenamic acid exhibits anti-angiogenic activities in pancreatic cancer tumors. 
Table II. Differences between tumor and normal endothelium/
vasculature.a 
–––––––––––––––––––––––––––––––––––––––––––––––––
Constant remodeling of tumor vessels
Increased vessel tortuosity
Lack of associated pericytes
Reliance on a tubulin cytoskeletal network for
functional integrity
Vessels thin walled and fragile
Increased interstitial pressure within tumor
Vessel marker immaturity
Greater vascular permeability 
Variable flow rates
Huge variability in vascular density
Lack of vascular smooth muscle
Lack of lymphatic drainage
Abnormalities of endothelial cell shape and function
–––––––––––––––––––––––––––––––––––––––––––––––––
aSeveral structural and functional changes are observed in tumor
endothelium/vasculature which impacts the tumor growth and
metastasis. A variety of characteristic changes occur due to tumor
formation are given in the table (37,94-101).
–––––––––––––––––––––––––––––––––––––––––––––––––
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b) Small molecule vascular-disruptive agents. It was noted
early on in the clinical evaluation of several compounds
including anti-neoplastic agents that some of these drugs
can induce vascular damage within tumors, but only at doses
approximating the maximum tolerated dose (MTD) which
has limited their clinical application (40,114-123). However,
several new vascular targeting agents are now in clinical
development since they are active at doses less than one-tenth
of the MTD used in murine models (124). Small-molecule
VDAs are divided primarily into two classes: agents that target
tubulin/microtubules (e.g., colchicine, podophyllotoxin, and
the vinca alkaloids vincristine and vinblastine), and other
anti-neoplastic agents that don't target tubulin/microtubules
(e.g., TNF-·, flavone acetic acid, and related compounds).
c) Tubulin-targeting agents. Interest in the vascular-damaging
aspects of tubulin binding agents was initiated by studies
with colchicines and vinca alkaloids, which demonstrated that
these agents could induce vascular shutdown in preclinical
tumor models, albeit at near toxic doses (16,115,119,125).
However, new compounds of this class have now been
developed and used at lower and more therapeutic relevant
doses. The following are some of these compounds that have
been investigated recently. 
i) Combretastatin A4 phosphate (CA4P) is a natural
compound that has been isolated from a South African tree
called Combretum caffrum. This tubulin inhibitor is a prodrug
that is rapidly dephosphorylated to the active compound
CA4 which is structurally similar to colchicines and binds
the colchicine-binding site on tubulin and inhibits tubulin
polymerization (66,126-128). Unlike colchicine and other
tubulin binding agents (vincristine and vin blastine), CA4P
can induce vascular collapse within tumors at doses less
than one-tenth of the MTD in murine models (124). These
preclinical data have demonstrated selective activity of CA4P
against proliferating endothelial cells in vitro. In addition,
in vivo data have shown a rapid shutdown of tumor vasculature
with resultant central tumor necrosis. 
A recent study has demonstrated evidence of an additional
mechanism through which CA4P can selectively disrupt the
new abnormal vasculature associated with disease processes
(129). These studies showed that CA4P can selectively
disengage vascular endothelial (VE)-cadherin interactions
between adjacent endothelial cells. Vascular endothelial
cadherin is a factor that supports the tumor's neo-vessels and
functions to enhance endothelial cell migration, survival,
vascular integrity, and assembly into tubular structures.
The disengagement of VE-cadherin interaction can lead to
endothelial cell detachment and apoptosis. The important
aspect of this study was that disengagement only occurred in
endothelial cells that lacked smooth muscle cell contact. It is
known that the lack of smooth muscle or pericyte support is a
feature of a neovasculature associated with disease processes. 
A phase I trial of CA4P has been reported in patients with
advanced solid tumors (130). Data have shown that CA4P
and its active metabolite CA4 displayed dose-dependent linear
increase in the area under the curve (AUC) with 0.47 h half-life
of CA4P and 4.2 h for CA4. At the dose level of 60 mg/m2
six of the seven patients had a significant decline in the
gradient peak tumor blood flow. CA4P demonstrated clinical
benefit with a sustained complete response in a patient with
anaplastic thyroid cancer, a minor response in a patient with
non-small-cell lung cancer, and prolonged stable disease for
more than a year in three patients with colon, medullary
thyroid, and renal cancers. Another phase I pharmacodynamic
trial of CA4P in patients with advanced solid tumors has been
performed attempting to obtain an optimal biological dose
for CA4P (131). These data have suggested that the optimal
biological dose for a phase II trial of CA4P is 52 mg/m2. This
dose level is below the MTD of 68 mg/m2 but was able to
achieve the biological effect of sustained reduction in tumor
blood flow.
A synthetic derivative of CA4P (AVE8062) has been
synthesized and studied in several tumor models. Preclinical
data have demonstrated that AVE8062 can inhibit microtubule
polymerization causing rapid vascular shutdown of tumor
blood flow in (Lejune, Proc Am Assoc Cancer Res 43, abs.
781, S156, 2002). However, early clinical results of AVE8062
have not yet been reported. 
ii) TZT-1027 is another tubulin binding agent that inhibits
microtubule assembly. It is a cytotoxic dolastatin-10 analog.
It has been demonstrated in in vivo models that TZT-1027
causes rapid tumor vascular collapse by a direct effect on
microtubules (132). 
A phase I clinical trial has been conducted with TZT-1027
in patients with advanced solid tumors (133). Data has shown
that 33% of patients treated with TZT-1027 had stable disease
as defined by RECIST criteria. Another phase I trial of
TZT-1027 in 17 patients treated on days 1 and 8 of a 3-week
course was reported (134). A partial response within 50 weeks
of treatment in a patient with metastatic liposarcoma was
observed. In a phase I study of TZT-1027 with carboplatin
has shown that there was one partial response seen in a
patient with pancreatic carcinoma, and seven patients had
stable disease (Blagen, Proc ASCO 23, abs. 3141, S226,
2005). 
iii) MN-029 is a pro-drug that is converted in vivo to the
active compound MN-022 by enzymatic hydrolysis. MN-029
inhibits tubulin polymerization by attaching to the colchicine
binding site, resulting in the disruption of the cytoskeleton.
This disruption of proliferating endothelial cells leads to
tumor ischemia and necrosis (118).
iv) ZD6126 is another VDA that has been shown to inter-
fere with the microtubular network of proliferating endothelial
cells supplying tumor vasculature (106,135). A phase I trial
of a single 10-min infusion of ZD6126 on day 1 and day 28
revealed that ZD6126 is rapidly metabolized to its active
metabolite ZD6126 phenol (Scurr, Proc ASCO 22, abs. 3083,
S215, 2004). Another trial has been conducted to assess the
effect of ZD6126 on tumor vasculature. Data have clearly
shown that the overall tumor enhancement curve (as assessed
by DCE-MRI) was decreased 13-84% from baseline values
at 6 h after ZD6126 infusion in five of six patients. However,
most of the effects were seen at the tumor center (DelProposto,
Proc ASCO 20, abs. 440, S111, 2002). 
d) Flavanoids and derivatives. Flavanoids such as flavone
acetic acid (FAA) and its derivative, 5,6 dimethylxanthenone-
4-acetic acid (DMXAA, Antisoma plc/Roche Holding AG)
are believed to exert their effects on blood vessels through
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the localized release of TNF· from activated macrophages
within the tumor tissue (136). The role of TNF· in flavone
anti-tumor activity was confirmed by the ability of TNF·
antibodies to inhibit FAA-induced vascular collapse (137,138).
DMXAA is also thought to increase nitric oxide and serotonin
as well as TNF· (139). The serotonin metabolite 5-hydroxy-
indole acetic acid (5-HIAA) is a marker of serotonin activity
and is indicative of platelet activation as a result of damaged
vascular endothelium. An in vivo study using a mouse model
has shown that administration of DMXAA reduced tumor
blood flow (as measured by DCE-MRI) and increased the
5-HIAA level. It has been suggested that 5-HIAA might be
a sensitive biological marker of blood flow changes induced
by DMXAA (140). One study was conducted to investigate
the effects of DMXAA on tumor perfusion in cancer patients
using DCE-MRI. These data have demonstrated that 50%
of patients experienced up to a 66% reduction of tumor blood
flow up to 24 h after drug infusion (141). These DCE-MRI
findings are consistent with DMXAA's vascular targeting
activity. Another phase I trial of 63 patients to assess DMXAA
activity has shown an unconfirmed partial response in a
patient with metastatic cervical cancer (142).
Two other small molecules have been shown to possess
VDA-like activity; they are trivalent arsenic trioxide and the
N-cadherin antagonist ADH-1 (Exherin; Adherex Technologies
Inc). The mechanism through which arsenic trioxide elicits
its vascular effects is, as yet, unknown and such effects have
only been observed at doses close to the MTD in rodent tumor
models (143). However, ADH-1 is a cyclic pentapeptide
that competitively antagonizes N-cadherin which mediates
cell adhesion between endothelial cells as well as between
endothelial cells and pericytes within the tumor vasculature.
This pentapeptide contains the cadherin cell adhesion
recognition sequence His-Ala-Val. An in vivo study with
tumor-bearing mice has shown that ADH-1 can induce
vascular damage and extensive tumor necrosis (109). The
preliminary phase I data of ADH-1 in 46 patients with
advanced solid tumors demonstrated that ADH-1 could be
dose escalated as a single intravenous infusion from 50 to
1,000 mg/m2 without reaching the MTD (144). From these
data it seems that ADH-1 is well tolerated. More research
needs to be done to confirm its anti-tumor activity. 
4. Combining VDAs with anti-angiogenic drugs
Although VDA produces extensive blood flow shutdown in
general, little suppression of tumor growth has been observed
following single doses. This observation has been attributed
to continued proliferation of the so-called ‘viable rim’ of
cells, which survive at the border between malignant and
normal tissue. Cells in the viable rim derive their nutritional
support from the vasculature associated with the normal
tissue, which is not affected by VDA treatment. However,
regrowth of the viable rim involves new blood vessel
development; therefore, the combination of VDAs and
anti-angiogenic drugs is an attractive approach that is actively
being investigated.
Despite the fact that both anti-angiogenic drugs and
VDAs target the tumor vasculature, it is important to recognize
that key differences exist between these agents (145). These
differences, as mentioned earlier in this review, apply to
their mode of action as well as to their likely therapeutic
applications. Taking these differences in consideration, it
should be clear from a therapeutic perspective that targeting
the tumor vasculature with anti-angiogenic agents and VDAs
would be complimentary. Preclinical evidence supporting the
notion of combining agents that target different aspects of the
tumor vasculature is beginning to accumulate. For example,
the effect of an anti-angiogenic drug such as bevacizumab,
which targets the VEGF extracellular receptor, could be
augmented with a VDA that targets the microtubular network
of the endothelial cells, subsequently causing rapid vascular
collapse. Since bevacizumab (anti-angiogenic agent) targets
the neovascularization of the tumor, the addition of a VDA
that inhibits more established tumor vascular endothelium
has been suggested to have a synergistic effect (13). Indeed,
it has been demonstrated that the combination of a VEGF
inhibitor (ZD6474) in combination with a VDA (ZD6126)
had greater anti-tumor effect than using either agent alone.
This effect has been observed in preclinical human models of
human renal cell carcinoma and Kaposi's sarcoma in nude
mice (146).
Another example is the combination of a selective tyrosine
kinase inhibitor associated with VEGFR2 and a microtubulin-
disrupting VDA (69,146). It has been demonstrated that this
combination significantly enhance tumor response beyond
that achieved with either vascular targeting therapy alone.
Other examples of such combinations of dual targeting of the
tumor vasculature are under active preclinical investigation
and these include the combination of CA4 and DMXAA with
bevacizumab. The clinical testing of this concept has started
with the combining of CA4P with bevacizumab in a recent a
phase I clinical trial. 
Nonetheless, the greatest benefits of vascular targeted
therapies are expected to lie in combination with conventional
anticancer therapies. Such approaches may improve treatment
outcomes by capitalizing on principles of enhanced anti-tumor
efficacy, non-overlapping toxicities and spatial cooperation. 
The strategy of combination therapy has already started in
a clinical phase I trial where single agent CA4P is also being
explored with radiotherapy. In a phase I trial, patients with
non-small-cell lung cancer or prostate cancer who were to
receive radiotherapy were eligible for CA4P treatment, which
was given as a single injection to half the participants and as
a weekly dose of 50 mg/m2 to the other half of the patients.
There was a mild increase in blood pressure as well as a drop
in the pulse rate after CA4P administration that returned to
baseline within 6 h after infusion. No acute or chronic toxicity
was seen when CA4P was given with radiotherapy, and the
cardiovascular side effects observed were mild and self-limiting
(147).
Recently the development of new agents with both anti-
angiogenic and vascular targeting properties has attracted
greater attention and a synthesized compound, C9 has been
investigated as a potential candidate with anti-angiogenic
activity and vascular-disruption properties (148-150). C9 is
a microtubule-binding agent and effectively targets tumor
vasculature. This compound impacts the morphology and
function of endothelial cells, involving the Raf-MEK-ERK
and Rho/Rho kinase signalling pathways (150). 
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5. Conclusions and future directions
The ultimate goal of cytotoxic chemotherapy is to directly kill
the highly dividing tumor cells. However, cytotoxic agents
are often associated with drug resistance which results in tumor
growth during the recovery period between doses or cycles
of chemotherapy. On the other hand, strategies using anti-
vascular novel agents (Fig. 4) that target vascular endothelial
functional integrity and endothelial cell survival pathways have
shown promising results in preclinical and clinical studies.
Targeting the tumor endothelium and vasculature offers
the attractive possibility of inducing responses in all tumor
types, lowering the risk of drug resistance and improving
the effectiveness of conventional clinically active cytotoxic
chemotherapies.
While VDAs can kill the central, poorly perfused regions
of the tumor, combination therapy with anti-angiogenic or
cytotoxic agents is required to kill the well perfused, rapidly
proliferating periphery of the tumor. The combinations are
believed to synergistic and enhance cell killing. Based on the
current preclinical data and the encouraging clinical findings
anti-angiogenic agents and VDA will establish themselves as
a new and distinct treatment approach in cancer therapy.
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